BC
GSK icon

Barrett & Company’s GSK GSK Stock Holding History

Barrett & Company’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$114K Buy
2,060
+6
+0.3% +$325 0.04% 193
2025
Q4 		$101K Sell
2,054
-794
-28% -$37K 0.03% 211
2025
Q3 		$123K Buy
2,848
+8
+0.3% +$312 0.04% 195
2025
Q2 		$109K Sell
2,840
-153
-5% -$5.85K 0.04% 199
2025
Q1 		$116K Sell
2,993
-118
-4% -$4.32K 0.05% 177
2024
Q4 		$105K Buy
3,111
+8
+0.3% +$288 0.04% 191
2024
Q3 		$127K Buy
3,103
+9
+0.3% +$368 0.06% 172
2024
Q2 		$119K Sell
3,094
-233
-7% -$9.8K 0.05% 175
2024
Q1 		$143K Sell
3,327
-392
-11% -$16.2K 0.07% 158
2023
Q4 		$138K Sell
3,719
-1,269
-25% -$45.6K 0.07% 151
2023
Q3 		$181K Sell
4,988
-1,573
-24% -$55.8K 0.11% 131
2023
Q2 		$234K Sell
6,561
-843
-11% -$30.2K 0.14% 114
2023
Q1 		$263K Sell
7,404
-824
-10% -$28.8K 0.17% 104
2022
Q4 		$289K Hold
8,228
– – 0.19% 96
2022
Q3 		$289K Buy
+8,228
New +$312K 0.19% 96

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Barrett & Company's GSK Position: Q1 2026 in Review

Barrett & Company increased its GSK (GSK) stake by 0.29% in Q1 2026, buying an estimated $325 and bringing the position to 2,060 shares worth $114K. The position accounts for 0.04% of the portfolio, ranked #193.

Barrett & Company first reported a position in GSK in Q3 2022 and has held it in 15 quarters since. The position peaked at $289K in Q4 2022. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Barrett & Company held 2,060 shares of GSK worth $114K as of Q1 2026.
  • Barrett & Company bought 6 GSK shares in Q1 2026, an estimated $325.
  • GSK made up 0.04% of Barrett & Company's portfolio in Q1 2026, its #193 holding.
  • Barrett & Company first reported a position in GSK in Q3 2022 and has held it in 15 quarters since.
  • Barrett & Company's GSK position peaked at $289K in Q4 2022.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Barrett & Company's 13F filing for Q1 2026, filed 4 May 2026.